Journal Article

<i>In vitro</i> anticandidal activity of xanthorrhizol isolated from <i>Curcuma xanthorrhiza</i> Roxb

Yaya Rukayadi, Dongeun Yong and Jae-Kwan Hwang

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 57, issue 6, pages 1231-1234
ISSN: 0305-7453
Published online April 2006 | e-ISSN: 1460-2091 | DOI: https://dx.doi.org/10.1093/jac/dkl132
In vitro anticandidal activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb

Show Summary Details

Preview

Objectives: Xanthorrhizol, isolated from the methanol extract of Curcuma xanthorrhiza Roxb., was investigated for its anticandidal activity using six Candida species.

Methods: The in vitro susceptibility tests for xanthorrhizol were carried out in terms of MIC and minimal fungicidal concentration (MFC) using the NCCLS M27-A2 broth microdilution method. Time–kill curves were determined to assess the correlation between MIC and fungicidal activity of xanthorrhizol at concentrations ranging from 0 MIC to 4× MIC.

Results: All Candida species showed susceptibility to xanthorrhizol in the MIC range 1.0–15.0 mg/L for Candida albicans, 1.0–10 mg/L for Candida glabrata, 2.0–8.0 mg/L for Candida guilliermondii, 2.5–7.5 mg/L for Candida krusei, 2.5–25 mg/L for Candida parapsilosis and 2.0–8.0 mg/L for Candida tropicalis. Time–kill curves demonstrated that xanthorrhizol was able to kill the Candida strains with MFCs of 20 mg/mL, 15 mg/mL, 12.5 mg/mL, 10 mg/L, 30 mg/mL and 10 mg/L for C. albicans, C. glabrata, C. guilliermondii, C. krusei, C. parapsilosis and C. tropicalis, respectively.

Conclusions: The potent anticandidal activity of xanthorrhizol may support the use of C. xanthorriza for the treatment of candidiasis.

Keywords: C. xanthorriza; MIC; MFC; antifungals

Journal Article.  2114 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.